October 5, 2018 Comments (0) Blog

Biozone Pharmaceuticals – Cocrystal Pharma

Biozone Pharmaceuticals

Investigating Potential claims – Biozone Pharmaceuticals (Cocrystal Pharma)

The White Law Group is investigating potential claims involving broker dealers who may have unsuitably recommended Biozone Pharmaceuticals to investors.

Biozone Pharmaceuticals is a clinical stage biotechnology company engaged in the discovery and development of “novel antiviral therapeutics that target the replication machinery of hepatitis viruses, influenza viruses, and noroviruses,” according to its website. The company recently changed its name to Cocrystal Pharma and trades on the Nasdaq exchange under the symbol COCP.

According to the complaint, a class action lawsuit has recently been filed against Biozone Pharmaceuticals. The class action complaint specifically alleges that during the period in question, September 23, 2013 through September 7, 2018, Biozone may have provided false and/or misleading material information, may have failed to disclose adverse material information to the public, in particular: the company was allegedly participating in a “pump-and-dump” scheme designed to artificially boost the price of its stock; that the pump-and-dump scheme would lead to regulatory scrutiny; that the company failed to comply with the Securities and Exchange Commission’s disclosure requirements; and that consequently the company’s statements to the public during the relevant period about its business, operations and prospects were false and misleading and/or had no reasonable basis. The complaint alleges that when true facts emerged, investors suffered losses.

Free Consultation with a Securities Attorney

Broker dealers are required to perform adequate due diligence on all investment recommendations. They must ensure that each investment is suitable for the investor in light of the investor’s age, risk tolerance, net worth, financial needs, and investment experience.

If a broker makes an unsuitable investment recommendations or fails to adequately disclose the risks associated with an investment they may be liable for investment losses.  FINRA operates the largest securities dispute resolution forum in the United States, and has extensive experience in providing a fair, efficient and effective venue to handle a securities-related dispute.

 If you are concerned about your investment in Biozone Pharmaceuticals or another investment, The White Law Group may be able to help you.  For a free consultation with a securities attorney, please contact The White Law Group at 1-888-637-5510.

The White Law Group is a national securities fraud, securities arbitration, and investor protection law firm with offices in Chicago, Illinois and Vero Beach, Florida. For more information on the firm, visit www.WhiteSecuritiesLaw.com.